Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Malaysia Proposes Biosimilars Guidance

This article was originally published in The Pink Sheet Daily

Executive Summary

Southeast Asia nation may be first in the area to regulate FOBs, but local companies aren’t ready to produce, analyst says.

You may also be interested in...



Japan Posts Draft Guidance On Biosimilars; Seeks Public Comment

TOKYO - Japan's Ministry of Health, Labor and Welfare Sept. 17 posted draft guidance on follow-on biologics, or biosimilars, a move that could make Japan among the first group of large economies to set a safety and regulatory framework for the new copycat breed of biologic therapies

New EPO Products Set To Boost Future Revenue For 3SBio

SHANGHAI - 3SBio generated revenues from increased sales of its recombinant human erythropoietin products but saw its earnings slip, according to the unaudited financial results for the second quarter ended June 30

Global Drug Regulators And Manufacturers Grapple With How To Ensure Global Quality Standards (Part 2 Of 2)

[Editor's note: This is part two of a two-part feature on ensuring drug quality, as discussed at the Fifth IFPMA Asian Regulatory Conference in Kuala Lumpur. Part one appeared in PharmAsia News, March 17, 2008.]

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS068386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel